(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 September 2021 (30.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/194425 A1

(51) International Patent Classification:
C12N 15/00 (2006.01) *A61P 35/00* (2006.01)
A61K 35/17 (2015.01)

(21) International Application Number:
PCT/SG2021/050166

(22) International Filing Date:
25 March 2021 (25.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/000,468 26 March 2020 (26.03.2020) US

(71) Applicants: **NATIONAL UNIVERSITY OF SINGAPORE** [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). **CORNELL UNIVERSITY** [US/US]; 395 Pine Tree Road, Suite 310, Ithaca, New York 14850 (US).

(72) Inventors: **LE, Thi Nguyet Minh**; c/o National University of Singapore, Yong Loo Lin School of Medicine / Department of Pharmacology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **VU, Tien Luyen**; c/o National University of Singapore, Yong Loo Lin School of Medicine / Department of Pharmacology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **GRIMSON, Andrew**; c/o Cornell University, Center for Technology Licensing, 395 Pine Tree Rd, Ithaca, NY 14850 (US). **RUDD, Brian**; c/o Cornell University, Center for Technology Licensing, 395 Pine Tree Rd, Ithaca, NY 14850 (US). **YEE MON, Kristel Joy**; c/o Cornell University, Center for Technology Licensing, 395 Pine Tree Rd, Ithaca, NY 14850 (US). **PHAM, Tuan Thach**; c/o National University of Singapore, Yong Loo Lin School of Medicine / Department of Pharmacology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **PENG, Boya**; c/o National University of Singapore, Yong Loo Lin School of Medicine / Department of Pharmacology, 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(74) Agent: **WITHERS KHATTARWONG LLP**; 80 Raffles Place, #25-01, UOB Plaza 1, Singapore 048624 (SG).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

WO 2021/194425 A1

(54) Title: METHOD OF DELIVERING NUCLEIC ACID TO IMMUNE CELLS USING RBCEV



Figure 1A

(57) Abstract: The invention relates to the use of red blood cells extracellular vesicle (RBCEV) to deliver nucleic acids to immune cells (e.g. T cells), wherein the nucleic acid cargoes are loaded into the RBCEV *in vitro* or *ex vivo*. The invention also relates to the prophylactic and therapeutic use of said immune cells in diseases, such as cancer.

[Continued on next page]

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*